Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical Officer
CAMBRIDGE, UK and MONTREAL, CANADA, 7 February 2025 — Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, announces the appointment of Dr. Klaus Edvardsen as its new Chief Medical Officer (CMO). Dr. Edvardsen, an accomplished oncology innovator and development leader, brings decades of clinical and strategic expertise to Epitopea as the company advances its pipeline of transformational cancer immunotherapies.
